A team of scientists has shown that intermittent fasting (reducing the number of hours of intake and extending the hours of fasting each day) is an effective method for losing weight and improves cardiovascular health in people with obesity problems.
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.
Importantly, the research found members who achieved a personalized weight-loss goal, generated by an AI tool within the program, experienced the greatest success.
Diabetes drugs have revolutionized the treatment of obesity, but the discovery of their potential weight loss benefits didn't happen right away.
Ten years after undergoing bariatric surgery as teens, over half of study participants demonstrated not only sustained weight loss, but also resolution of obesity-related conditions, such as type 2 diabetes, high blood pressure and high cholesterol, according to the report published in the New England Journal of Medicine.
